山东国曜琴岛(济南)律师事务所 关于辰欣药业股份有限公司 2025年第二次临时股东大会的 法律意见书 山东国曜 律师事务所 号国曜琴岛律师楼 济南市历下 7665 电话:0531-58681777 二〇二五年九月 始于1956 · 缔造百年律所 ENTURY-OLD LAW FIRM 始于1956 · 缔造百年律所 山东国曜琴岛(济南)律师事务所 关于辰欣药业股份有限公司 2025年第二次临时股东大会的法律意见书 【2025】国曜琴岛(济南)非诉字第294号 致:辰欣药业股份有限公司 山东国曜琴岛(济南)律师事务所(以下简称"本所")接受辰欣药业股份 有限公司(以下简称"辰欣药业"、"公司")的委托,指派本所律师出席公司 于2025年9月16日召开的2025年第二次临时股东大会(以下简称"本次股东大会" ）。本所律师根据《中华人民共和国证券法》(以下简称"《证券法》")、《 中华人民共和国公司法》(以下简称"《公司法》")、《上市公司股东会规则》 等现行有效的法律、法规、规范性文件以及《辰欣药业股份有限公司章程》（以 下简称"《公司章程》")的有关规定,就本次股东大会的相关事宜出具本法律 意见书。 为出具本法 ...

Group 1 - The Jining government is focusing on building a modern pharmaceutical industry hub, highlighted by a recent press conference featuring key local pharmaceutical companies [1][3] - The "chain leader system" has been adopted as a key initiative to promote industrial economic development, leading to positive monthly progress in the pharmaceutical sector [3] - Jining has a solid foundation in the modern pharmaceutical industry with 67 large-scale enterprises, including 6 chain leader companies and various recognized specialized firms [3] Group 2 - The modern pharmaceutical industry chain in Jining consists of three core sectors: chemical pharmaceuticals, modern traditional Chinese medicine, and medical devices [4] - The chemical pharmaceutical sector focuses on an integrated development model of raw materials and formulations, leveraging cost-effectiveness and quality advantages [4] - The modern traditional Chinese medicine sector aims to create a distinctive brand based on local aquatic medicinal resources, while the medical device sector is expanding into high-end medical equipment [4] - Future developments will target breakthroughs in biopharmaceuticals, modernization of traditional Chinese medicine formulations, and high-end medical device research [4]

Core Insights - Chenxin Pharmaceutical is a comprehensive pharmaceutical enterprise engaged in R&D, production, and sales, listed on the Shanghai Stock Exchange in September 2017 [1] - The company has established a strong production capacity, leading in both large-volume and small-volume injection production in China [1][3] - R&D innovation is a core strategic focus, with significant investment in technology and collaboration with over 30 research institutions [4] Group 1: Company Overview - Chenxin Pharmaceutical has over 5,000 employees and offers more than 400 specifications of various dosage forms [1] - The company has completed an industrial layout with four major production bases and five industrial parks [3] - R&D personnel exceed 600, with over 70% holding advanced degrees, and R&D investment accounts for approximately 10% of revenue [3] Group 2: R&D and Innovation - The company invests nearly 400 million yuan annually in R&D innovation, establishing a solid foundation for technological competitiveness [4] - Chenxin focuses on high-end generic drugs, OTC external medications, innovative drugs, and special medical foods, creating a virtuous cycle of production and development [4][5] - Future goals include advancing 1-2 new Class 1 drugs into clinical Phase I each year and launching one Class 1 drug within five years [5] Group 3: Production and Technology - Production is the foundational aspect of Chenxin, emphasizing large-scale capacity, intelligent manufacturing, and standardized quality control [6] - The company integrates advanced technologies such as big data and AI into its manufacturing processes, aiming for a smart manufacturing benchmark in the pharmaceutical industry [6] - Annual investments of no less than 300 million yuan will be directed towards technological upgrades and automation [6] Group 4: Marketing and Industry Chain - The marketing system effectively translates the company's internal value into market results, covering hospitals, grassroots medical institutions, and retail terminals [8] - Chenxin aims to enhance its competitive advantage by integrating raw materials and formulations, ensuring product quality and supply chain stability [8] - The company is exploring new paths in health management and elder care services, expanding its business boundaries [8]

Group 1 - The special medical food market has significant potential, with Shandong province being an early player and ranking second in the number of production enterprises nationwide [2] - Chenxin Pharmaceutical has been deeply involved in the special medical food sector for nearly 10 years, obtaining five product registration approvals and collaborating with 200-300 hospitals [2][3] - The company has broken the long-standing monopoly of international corporations in the field by securing the first batch of national approvals for liquid full-nutrition special medical food [2][4] Group 2 - The high barriers to entry and strict regulations characterize the special medical food industry, with Chenxin developing a "step sterilization process" to balance sterilization effectiveness and nutrient retention [3][4] - The company has successfully developed a unique oil-water online mixing technology to address challenges in product formulation, ensuring stability and quality [4][7] - Chenxin's liquid special medical food is designed for individuals with restricted eating capabilities and can be administered via nasal feeding [3][4] Group 3 - The company has strengthened its R&D capabilities, with some products being prioritized for expedited review by the National Market Supervision Administration [5][6] - The "Xinsulin special medical use diabetes full-nutrition formula food" is set to enter a fast-track approval process, significantly reducing the approval time from about one year to six months [6] - The R&D for diabetes-specific nutrition has taken nearly two years, highlighting the complexity and challenges in developing liquid formulations compared to powder products [6][7] Group 4 - Chenxin has established a rigorous production system, utilizing automated production lines and a three-stage air filtration system to ensure product quality [3][7] - The company collaborates with various research institutions to enhance its R&D and industrialization capabilities in the special medical food sector [7]

辰欣药业股份有限公司 2025 年第二次临时股东大会会议资料 辰欣药业股份有限公司 2025 年第二次临时股东大会 会议资料 二 0 二五年九月 1 / 14 辰欣药业股份有限公司 2025 年第二次临时股东大会会议资料 辰欣药业股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，根据《中华 人民共和国公司法》《公司章程》制定本须知，望出席辰欣药业股份有限公司（以下简 称"公司"或"辰欣药业"）股东大会的全体人员遵照执行。 一、参会资格：本次股东大会股权登记日下午收市后在中国证券登记结算有限责任 公司上海分公司登记在册的公司股东。 二、会议期间全体出席会议人员应以维护股东合法权益，确保大会正常进行，提高 议事效率为原则，认真履行法定职责。请与会者维护现场秩序，会议期间请勿大声喧哗。 三、为保证股东大会的严肃性和正常秩序，除依法出席会议的公司股东（或其代理 人）、董事、监事、董事会秘书、高级管理人员、聘请的律师和董事会邀请参会的人员、 会务工作人员外，公司有权依法拒绝其他人士入场。 四、由公司董事会秘书负责本次大会的会务事宜。 五、出席本次会议的股 ...

9月9日，辰欣药业盘中下跌2.04%，截至09:54，报22.57元/股，成交1.82亿元，换手率1.76%，总市值 102.19亿元。 分红方面，辰欣药业A股上市后累计派现11.12亿元。近三年，累计派现5.48亿元。 资金流向方面，主力资金净流出1856.01万元，特大单买入368.45万元，占比2.02%，卖出389.77万元， 占比2.14%；大单买入2301.27万元，占比12.63%，卖出4135.96万元，占比22.71%。 辰欣药业今年以来股价涨66.94%，近5个交易日跌7.69%，近20日跌32.57%，近60日涨58.16%。 资料显示，辰欣药业股份有限公司位于山东省济宁市高新区同济路16号，成立日期1998年11月6日，上 市日期2017年9月29日，公司主营业务涉及从事化学制剂药物的研究开发和生产经营业务。主营业务收 入构成为：大输液42.66%，小容量注射剂29.80%，口服固体制剂13.98%，滴剂4.31%，冻干粉针剂 3.68%，膏剂3.43%，原料药1.35%，冲洗剂0.59%，其他(补充)0.20%。 今年以来辰欣药业已经4次登上龙虎榜，最近一次登上龙虎榜为9月3日，当日 ...

Market Overview - The chemical pharmaceutical sector experienced a slight decline of 0.05% on September 8, with Chenxin Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Jincheng Pharmaceutical (300233) with a closing price of 20.83, up 7.04% and a trading volume of 452,000 shares, totaling 934 million yuan [1] - Haichen Pharmaceutical (300584) closed at 77.88, up 6.39% with a trading volume of 196,500 shares, totaling 1.481 billion yuan [1] - Fosun Pharmaceutical (600196) closed at 32.08, up 6.26% with a trading volume of 912,400 shares, totaling 2.928 billion yuan [1] - Conversely, the following companies faced significant declines: - Chenxin Pharmaceutical (603367) closed at 23.04, down 8.61% with a trading volume of 318,300 shares, totaling 758 million yuan [2] - Maiwei Biotechnology (688062) closed at 53.60, down 7.94% with a trading volume of 198,400 shares, totaling 1.082 billion yuan [2] - Yifang Biotechnology (688382) closed at 38.40, down 7.85% with a trading volume of 172,300 shares, totaling 667 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.254 billion yuan from institutional investors, while retail investors contributed a net inflow of 922 million yuan [2] - The following stocks had notable capital flows: - Renfu Pharmaceutical (600079) had a net inflow of 97.1863 million yuan from institutional investors, but a net outflow of 85.0615 million yuan from retail investors [3] - Xintai (002294) saw a net inflow of 64.6380 million yuan from institutional investors, with retail investors experiencing a net outflow of 32.4393 million yuan [3] - Haichen Pharmaceutical (300584) had a net inflow of 33.1330 million yuan from institutional investors, but a net outflow of 92.6533 million yuan from retail investors [3]

天弘优质成长企业精选混合发起式A（007202）成立日期2019年10月18日，最新规模9344.04万。今年以 来收益16.27%，同类排名4451/8248；近一年收益33.6%，同类排名4240/8051；成立以来收益95.61%。 天弘优质成长企业精选混合发起式A（007202）基金经理为陆骥。 9月8日，辰欣药业跌5.08%，截至发稿，报23.93元/股，成交2.88亿元，换手率2.58%，总市值108.34亿 元。 资料显示，辰欣药业股份有限公司位于山东省济宁市高新区同济路16号，成立日期1998年11月6日，上 市日期2017年9月29日，公司主营业务涉及从事化学制剂药物的研究开发和生产经营业务。主营业务收 入构成为：大输液42.66%，小容量注射剂29.80%，口服固体制剂13.98%，滴剂4.31%，冻干粉针剂 3.68%，膏剂3.43%，原料药1.35%，冲洗剂0.59%，其他(补充)0.20%。 从基金十大重仓股角度 数据显示，天弘基金旗下1只基金重仓辰欣药业。天弘优质成长企业精选混合发起式A（007202）二季 度持有股数17.04万股，占基金净值比例为2.41%，位居第九大重仓股。根 ...

Core Insights - On September 3, the Shanghai Composite Index fell by 1.16%, with institutional investors appearing on the trading lists of 26 stocks, net buying 13 and net selling 13 [1][2]. Institutional Trading Summary - The stock with the highest net institutional buying was Chenxin Pharmaceutical, which closed at the daily limit with a gain of 10.02% and a turnover rate of 5.97%, resulting in a total transaction amount of 696 million yuan. Institutional seats accounted for a net purchase of 115.76 million yuan [2][5]. - Xiaocheng Technology saw a decline of 3.46% with a turnover rate of 33.97% and a total transaction amount of 1.812 billion yuan, leading to a net institutional buying of 110.91 million yuan despite a net outflow of 707.76 million yuan [2][5]. - Airo Energy experienced a significant increase of 19.15% with a turnover rate of 10.07% and a total transaction amount of 707 million yuan, resulting in a net institutional buying of 72.55 million yuan [3][5]. Market Performance - The average increase of stocks with net institutional buying was 7.73%, outperforming the Shanghai Composite Index. Notable performers included Kexin Electromechanical and Shangneng Electric, both closing at the daily limit [3][4]. - A backtest of stocks with net institutional buying over the past month showed a 48.60% probability of rising the next day and a 46.11% probability of outperforming the Shanghai Composite Index [3]. Net Selling Summary - The stock with the highest net institutional selling was Jilun Intelligent, which had a turnover rate of 32.87%, leading to a net selling of 98.80 million yuan [3][5]. - Fourchuang Electronics and Chengfei Integration also saw significant net selling, with amounts of 79.43 million yuan and 73.89 million yuan respectively [4][5]. Stock Connect Activity - On September 3, 21 stocks on the trading list had either Shanghai or Shenzhen Stock Connect participation, with notable net buying in stocks like Yanshan Technology and Sanwei Communication, amounting to 280.16 million yuan and 113.93 million yuan respectively [6][7]. - Conversely, significant net selling was observed in stocks such as Huasheng Tiancheng and Chenxin Pharmaceutical, with amounts of 270 million yuan and 54.72 million yuan respectively [6][8].

Core Insights - On September 3, the Shanghai Composite Index fell by 1.16%, with institutional investors appearing on the trading lists of 26 stocks, net buying 13 and net selling 13 [1][2]. Institutional Trading Summary - The stock with the highest net buying from institutional seats was Chenxin Pharmaceutical, which closed at the daily limit with a gain of 10.02% and a turnover rate of 5.97%, with a total transaction amount of 696 million yuan. Institutional seats accounted for a net purchase of 115.76 million yuan [2][5]. - Xiaocheng Technology saw a decline of 3.46% and a high turnover rate of 33.97%, with a total transaction amount of 1.812 billion yuan. Institutional seats net bought 110.91 million yuan, but the stock experienced a net outflow of 70.78 million yuan [2][5]. - Airo Energy rose by 19.15% with a turnover rate of 10.07% and a transaction amount of 707 million yuan. Institutional seats net bought 72.55 million yuan, while there was a net outflow of 44.77 million yuan [3][5]. Performance of Net Bought Stocks - Stocks with net institutional buying averaged a gain of 7.73%, outperforming the Shanghai Composite Index. Notable performers included Kexin Machinery and Shangneng Electric, both closing at the daily limit [3][4]. - The probability of stocks with net institutional buying rising the next day is 48.60%, with a 46.11% chance of outperforming the index [3]. Performance of Net Sold Stocks - The stock with the highest net selling by institutions was Julun Intelligent, which had a turnover rate of 32.87% and a net selling amount of 98.80 million yuan. The stock experienced a net outflow of 727 million yuan [3][5]. - Fourchuang Electronics and Chengfei Integration also saw significant net selling, with net outflows of 72.35 million yuan and 73.89 million yuan, respectively [4][5]. Stock Connect Activity - On September 3, 21 stocks on the trading list had either Shanghai or Shenzhen Stock Connect participation, with net buying seen in stocks like Yanshan Technology and Sanwei Communication, amounting to 280 million yuan and 114 million yuan, respectively [7][8]. - Notable net selling included Huasheng Technology and Chenxin Pharmaceutical, with net selling amounts of 270 million yuan and 54.72 million yuan, respectively [7][8].